Wedbush Reiterates Outperform Rating for Hemab Therapeutics (NASDAQ:COAG)

Hemab Therapeutics (NASDAQ:COAG)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $55.00 price target on the stock. Wedbush’s price objective would indicate a potential upside of 44.62% from the stock’s previous close.

COAG has been the subject of a number of other research reports. HC Wainwright lifted their price objective on Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group began coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 target price on the stock. Evercore started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target for the company. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.40.

Hemab Therapeutics Stock Performance

Shares of NASDAQ:COAG opened at $38.03 on Monday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $38.87. The company has a market capitalization of $1.78 billion and a PE ratio of -1.59. The business has a 50 day moving average price of $28.51.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock in a transaction on Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired a total of 2,970,541 shares of company stock worth $55,459,603 over the last ninety days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.